U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07115004) titled 'Phase 3 Study to Evaluate Subcutaneous (SC) VGA039 in Subjects With Von Willebrand Disease (VWD) (VIVID-6)..' on Aug. 04.
Brief Summary: This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Von Willebrand Disease (VWD)
Intervention:
DRUG: VGA039
VGA039 SC administered for 49-weeks during the interventional phase following a 24-week observational period.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vega Therapeutics, Inc
Published by HT Digital Content Services with permission from Health Daily Di...